This report evaluates the effectiveness of Statin Recombinant Drug (RSD) on managing metabolic syndrome. The study shows significant benefits of the drug in reducing the levels of glucose, insulin, triglycerides, and total cholesterol of patients. The report discusses the prevalence of metabolic syndrome, the use of statin in managing dyslipidemia, and the limitations of statin therapy. The study adopted a randomized double-blind parallel study evaluating the efficacy and effects of the new drug on metabolic syndrome. The results showed that the new recombinants drug is effective and shows statistical significance on the levels of glucose, insulin, total cholesterol, and triglycerides. The drug shows an effective way of lowering the cholesterol levels of the patients.